Sodium Ascorbate
Phase 1Small molecule
Sodium Ascorbate is one of 62 small molecule programs targeting Septic Shock. It is currently in Phase 1.
2
Indications
2
Total Trials
0
Active Trials
61
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
836 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Zepzelca
Jazz PharmaceuticalsPhase 3
Taxotere
AAvyxa
Phase 3
Piqray
NovartisPhase 3
Yondelis
AApotex Inc.
Phase 3
Vepesid
AAvyxa
Phase 3
Jemperli
GGlaxo Dba Glaxosmithkline
Phase 3
Liposomal Doxorubicin
Eli LillyPhase 3
Arimidex
IIstituto Clinico Humanitas
Phase 3
Trastuzumab Deruxtecan
AstraZenecaPhase 3
AK104
AAkeso
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sodium Ascorbate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- JJeanne Drisko, MD, CNS, FACN